Kayode Ogunniyi MD, MRCP(UK)
@dr_arkad
Followers
2K
Following
7K
Media
53
Statuses
8K
https://t.co/llCbjD6e7w
New York, USA
Joined December 2016
https://t.co/nNJH5JOzOg Our team is delighted to share our recently published article: “Advances in Non-statin Lipid Therapies: A Narrative Review of Evolving Strategies for Cardiovascular Risk Reduction” in the American Journal of Cardiovascular Drugs. Drawing from 138
1
16
66
La Valse au Clair de Lune (new version)
15
162
663
Any movie with Giancarlo Esposito is a definite watch
0
0
0
Exciting new option to lower #apoB #ldl #nonHdlc and Lp(a) @nationallipid @ASPCardio @CMHC_CME @society_eas @BCMHeart @Texas_Heart @BCM_CVRI @BCMFromtheLabs @BCMDeptMedicine @LaylaAbushamat @PamelaBMorris @PamTaubMD @rblument1 @DrMarthaGulati @pnatarajanmd
@JAMACardio @JAMAInternalMed @JAMANetworkOpen @AHAScience Among adults with HeFH who were already taking statin therapy, treatment with enlicitide was well tolerated and reduced levels of LDL-C, apolipoprotein B, non–HDL-C, and lipoprotein(a). #AHA25 @AHAScience
https://t.co/948f36sQ14
0
14
42
Special thanks to trainees, colleagues, collaborators and friends @yakoubenehasan @LaylaAbushamat @hwubcm @virani_md @AnumSaeedMD @AKulkarniMD Vijay Nambi RonHoogeveen @EugeniaGianos @ProfSNicholls @ProfKausikRay @BCMHeart @BCM_CVRI @nationallipid @CMHC_CME
Congratulations to @CBallantyneMD on receiving the AHA Distinguished Scientist Award! His groundbreaking work continues to shape and inspire cardiovascular medicine. https://t.co/9LRciF4u4k hashtag#AHA2025 hashtag#Cardiology hashtag#TexasHeartatBCM hashtag#distiguishedscientist
6
5
50
Cardiovascular disease is a leading cause of maternal complications. Telehealth, wearables & remote monitoring enable early detection and personalized care, improving outcomes and access. https://t.co/UrWH1u6J4U
#MaternalHealth #CardioObstetrics #DigitalHealth #HealthEquity
0
9
58
#AHA2025 - looking forward to IL-1 Blockade in Patients With STEMI: a Pooled Analysis of Randomized Clinical Trials of Anakinra and Goflikicept | Circulation https://t.co/3HNqLM81K2
@UVACVRC @VCUHealthHeart @VCUPharmacy @micheleg1390 @bvantassell @PaulCremerMD @SempreRossa
ahajournals.org
Background: STEMI triggers an intense inflammatory response and Interleukin-1 (IL-1) is associated with adverse cardiovascular outcomes, including heart failure (HF). IL-1 blockade with anakinra or...
0
5
16
NEW on Heart Rhythm TV: How do GLP-1 receptor agonists impact outcomes in patients with AF? 🫀 In this episode of @CardioNerds Journal Club, Jeanne du Fay de Lavallaz, MD, and @RamyDossMD are joined by @VarunSundaram4 and @CardiacepPA to break down the landmark TRANSFORM-AF
0
4
7
BREAKING: In the latest #HRStv Journal Club, @DanielAlyeshmer and @atulverma_md break down the OCEAN trial, a late-breaking clinical trial from #AHA2025 exploring anticoagulation vs. low-dose aspirin after successful atrial fibrillation ablation. See the full interview here
0
14
37
LAAC vs best medical care Thrombotic events - higher Bleeding events -- higher (counting procedure; also see AVERROES) CV death -- higher (please don't dare tell me that it was noise because if you do, let's relook at PROTECT and PREVAIL LAAC done in experienced labs
6
45
152
In my view, people don’t give APOC3 nearly as much credit as they give PCSK9. Honestly, APOC3 inhibition might end up being far more life-transforming. Before PCSK9 inhibitors, we already had statins that revolutionized LDL-C lowering. PCSK9 added value, but its market impact
When I was a medical student, I vividly recall taking care of very very sick patients with acute pancreatitis in the ICU. Remarkable to see how APOC3 inhibition (here, olezarsen) is now shown to be a highly effective therapy for severe hypertriglyceridemia, esp among those with
8
20
132
Honored to receive this award from @American_Heart thanks to many great mentors, collaborators and trainees @vijay_nambi @hwubcm @LaylaAbushamat @ProfKausikRay @virani_md @LizSelvin @Texas_Heart @BCMHeart @ChiadiNdumele @BCM_CVRI
BCM @bcmhouston cardiologist @CBallantyneMD named a 2025 Distinguished #Scientist by the @American_Heart Association. @BCMDeptMedicine
https://t.co/qFQ71WlEu1
33
8
106
CORALreef Lipids Trial presented by Ann Marie Navar @UTSWMedCenter #AHA25 🫀 Pivotal phase 3 trial of enlicitide decanoate, a once-daily oral PCSK9 inhibitor (macrocyclic peptide), added to background lipid-lowering therapy 🫀 2:1 randomization: enlicitide 20 mg PO daily vs
3
15
59
PCSK9 inhibition (evolocumab) saves lives. 25% relative risk reduction (3-point MACE; coronary heart disease death, MI, ischemic stroke) 20% reduction in overall mortality!!! 12,257 patients, all without prior ASCVD event; 55% LDL-C reduction from median xxx to 45 mg/dl
nejm.org
The proprotein convertase subtilisin–kexin type 9 (PCSK9) inhibitor evolocumab reduces the risk of major adverse cardiovascular events (MACE) among patients with a previous myocardial infarction, s...
17
57
237
In patients w severe hypertriglyceridemia, novel DR10624 -GLP-1/GCG chimeric peptide used in phase 2 study found to ⬇️ TG, liver fat & lipids w favorable safety profile #AHA2025 Phase 3 of DR10624 with lipid analysis (e.g., LDL particle number & subtypes) to be done in pts w
1
6
16
#VESALIUS-CV is the first large-scale randomized trial of a PCSK9 inhibitor (evolocumab) in primary prevention, showing that aggressive LDL-C lowering reduces first major cardiovascular events in patients without prior MI or stroke. This confirms that atherosclerotic risk begins
#VESALIUSCV trial #LBCT #AHA25 #VESALIUS 🫀RCT: role of PCSK9i in those without ASCVD (primary prevention in those at high risk) with LDL>90 on background of lipid lowering tx; followed for 4.5 y 🫀43% women 👏🏽👏🏽 🫀mean LDL 121 with LDL⤵️ with tx to 45 💥19% relative risk
1
22
74
When I was a medical student, I vividly recall taking care of very very sick patients with acute pancreatitis in the ICU. Remarkable to see how APOC3 inhibition (here, olezarsen) is now shown to be a highly effective therapy for severe hypertriglyceridemia, esp among those with
11
84
526
In moderate AS #AHA2025 Phase 2 study of 23 pts Ataciguat 200 mg QD tested if ataciguat slowed AVC progression, AVA narrowing, & cardiac structure & function by #echofirst parameters Finds ⬇️AV resistance for given orifice area, ⬆️leaflet compliance, LV remodeling
1
8
21
#AHA25 We have data on promising asymptomatic AS treatment in recent studies like EARLY TAVR, AVATAR, and RECOVERY but nothing to slow the progression. This is small phase II study but hope this benefit persists in the later phases. PS Ataciguat has failed to show any benefit
In moderate AS #AHA2025 Phase 2 study of 23 pts Ataciguat 200 mg QD tested if ataciguat slowed AVC progression, AVA narrowing, & cardiac structure & function by #echofirst parameters Finds ⬇️AV resistance for given orifice area, ⬆️leaflet compliance, LV remodeling
1
8
33
Another #CVprev trial we await at #AHA25 is the 💡 BETTER-BP Trial Can behavioral nudges beat hypertension? BETTER-BP uses digital prompts & incentives—grounded in behavioral economics—to keep blood pressure in check. Smart habits meet smart science. #Hypertension
1
5
15